Lion Biotechnologies Submits INDA to Conduct Cancer Studies
Lion Biotechnologies, Inc. recently announced it has filed an INDA with the US FDA to conduct clinical trials of LN-145 in the treatment of cervical cancer, and head and neck squamous cell carcinoma (HNSCC).
“This INDA filing represents an important milestone for Lion as we focus on expanding clinical applications of our core TIL technology,” said Elma Hawkins, PhD, Lion’s President and Chief Executive Officer. “In a study conducted and published by the National Cancer Institute, TIL have demonstrated encouraging anti-tumor activity in cervical cancer with two patients showing durable, complete remissions out of 9 patients. We are excited to be developing potentially new treatment options in these critical indications.”
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company’s lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit www.lionbio.com.
Total Page Views: 923
